Trial intelligence / Profile preview

Edoxaban vs Dalteparin in Hip Replacement

NCT00398216Phase 2Completed

Sponsor
Daiichi Sankyo Co., Ltd.
Start
May 2006
Primary completion
Jun 2007
Modality
Small Molecules
Countries
7
01

Overview

Phase 2, randomised, double-blind trial of edoxaban in venous thromboembolism (VTE) (5 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Adjudicated Incidence of Venous Thromboembolism. Started May 2006; status: completed.

02

Drugs

edoxaban
03

Conditions

venous thromboembolism (VTE)

Beyond the preview

Go deeper on NCT00398216.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00398216.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call